- Home
- NXDT vs ADCT Comparison
NXDT vs ADCT Comparison
Compare NXDT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXDT
- ADCT
- Stock Information
- Founded
- NXDT 2012
- ADCT 2011
- Country
- NXDT United States
- ADCT Switzerland
- Employees
- NXDT N/A
- ADCT N/A
- Industry
- NXDT Investment Managers
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NXDT Finance
- ADCT Health Care
- Exchange
- NXDT Nasdaq
- ADCT Nasdaq
- Market Cap
- NXDT 238.6M
- ADCT 224.3M
- IPO Year
- NXDT N/A
- ADCT 2020
- Fundamental
- Price
- NXDT $6.80
- ADCT $1.92
- Analyst Decision
- NXDT
- ADCT Strong Buy
- Analyst Count
- NXDT 0
- ADCT 5
- Target Price
- NXDT N/A
- ADCT $8.00
- AVG Volume (30 Days)
- NXDT 133.6K
- ADCT 1.6M
- Earning Date
- NXDT 01-01-0001
- ADCT 11-07-2024
- Dividend Yield
- NXDT 9.66%
- ADCT N/A
- EPS Growth
- NXDT N/A
- ADCT N/A
- EPS
- NXDT 0.99
- ADCT N/A
- Revenue
- NXDT N/A
- ADCT $70,717,000.00
- Revenue This Year
- NXDT N/A
- ADCT $6.58
- Revenue Next Year
- NXDT N/A
- ADCT $11.78
- P/E Ratio
- NXDT $6.41
- ADCT N/A
- Revenue Growth
- NXDT N/A
- ADCT N/A
- 52 Week Low
- NXDT $5.89
- ADCT $1.18
- 52 Week High
- NXDT $13.07
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- NXDT 77.63
- ADCT 45.58
- Support Level
- NXDT $5.28
- ADCT $1.80
- Resistance Level
- NXDT $7.22
- ADCT $3.49
- Average True Range (ATR)
- NXDT 0.28
- ADCT 0.40
- MACD
- NXDT 0.18
- ADCT -0.02
- Stochastic Oscillator
- NXDT 93.30
- ADCT 21.01
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. Revenue sources include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates primarily through its operating partnership and wholly owned subsidiaries.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.